OKYO Pharma (OKYO) CSO discloses stock and option positions
Rhea-AI Filing Summary
OKYO Pharma Ltd reports that Chief Scientific Officer Rajkumar V. Patil holds common stock and multiple stock option awards as of March 18, 2026. Direct common stock holdings total 16,667 shares. The options cover various grants over common stock with exercise prices between $1.46 and $2.75, including tranches such as 59,615 and 23,126 underlying shares, with expirations from 2033 through 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary
21 transactions reported
Mixed
21 txns
Insider
Patil Rajkumar V.
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Common stock | -- | -- | -- |
Holdings After Transaction:
Options — 575,000 shares (Direct);
Common stock — 16,667 shares (Direct)
Key Figures
Common stock held: 16,667 shares
Option exercise price: $2.13 per share
Option exercise price: $1.46 per share
+3 more
6 metrics
Common stock held
16,667 shares
Direct OKYO Pharma common stock holdings as of 2026-03-18
Option exercise price
$2.13 per share
Options over 59,615 common shares expiring 2033-03-14
Option exercise price
$1.46 per share
Options over 6,666 common shares expiring 2034-03-13
Option exercise price
$1.60 per share
Options over 23,126 common shares expiring 2035-01-29
Option exercise price
$1.50 per share
Options over 18,500 common shares expiring 2035-03-25
Option exercise price
$2.75 per share
Options over 45,750 common shares expiring 2035-07-10
Key Terms
conversion_or_exercise_price, underlying_security_title, expiration_date
3 terms
conversion_or_exercise_price financial
""conversion_or_exercise_price": "2.1300""
underlying_security_title financial
""underlying_security_title": "common stock""
expiration_date financial
""expiration_date": "2035-07-10""
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Who is the insider in OKYO (OKYO) covered by this Form 3?
The Form 3 covers Rajkumar V. Patil, who serves as Chief Scientific Officer of OKYO Pharma Ltd. The filing lists his direct holdings of common stock and several stock option awards over OKYO common shares.
What stock option grants are reported for OKYO (OKYO) Chief Scientific Officer?
The Form 3 lists multiple option awards over OKYO common stock with exercise prices of $1.46, $1.50, $1.60, $2.13, and $2.75. Individual tranches include 59,615, 23,126, and 45,750 underlying shares, among other grant sizes.
When do the reported OKYO (OKYO) options held by the CSO expire?
The reported stock options expire between 2033 and 2035. Expiration dates include 2033-03-14, 2034-03-13, 2035-01-29, 2035-03-25, and 2035-07-10, depending on the specific grant and exercise price.
What are example strike prices on the OKYO (OKYO) options reported?
The options show conversion or exercise prices of $2.13, $1.46, $1.60, $1.50, and $2.75 per share. Each price applies to a separate option grant over OKYO common stock with its own underlying share amount and expiration date.
Does this OKYO (OKYO) Form 3 show any insider buying or selling activity?
No. All entries are classified as holdings, and buyCount and sellCount are both 0 in the transaction summary. The filing presents an initial statement of positions rather than new purchase or sale transactions.